

PACIFIC DIAGNOSTIC LABORATORIES
PDL (Outreach Lab Only)
Antimicrobial Susceptibility Profile January – December 2021
Percent Susceptible¹

ORGANISM ¹	AVG. SAMPLE SIZE	AMPICILLIN	AMP / SUL	NAFCIL / OXACIL	PIP / TAZO	TETRACYCLINE	CEFAZOLIN	CEFTRIAXONE	CEFTAZIDIME	CEFEPIME	CIPROFLOXACIN	LEVOFLOXACIN	GENTAMICIN	IMIPENEM	ERTAPENEM	TRIMETH / SULFA	NITROFURAN (3)	CLINDAMYCIN	ERYTHROMYCIN	VANCOMYCIN	LINEZOLID	RIFAMPIN (4)	MEROPENEM
<i>Escherichia coli</i> (all)	10632	62	68		97		91	93	93	99	85	85	92	100	100	78	97						99
<i>Escherichia coli</i> ESBL ⁷ (all)	724	0	0		91		0	0	0	85	34	34	67	99	100	52	91						100
<i>Escherichia coli</i> (Urines)	10338	62	68		97		91	93	93	99	85	85	92	100	100	78	97						
<i>Escherichia coli</i> ESBL ⁷ (Urines)	702	0	0		91		0	0	0	84	34	34	68	99	100	52	91						
<i>Klebsiella pneumoniae</i>	1528		87		96		95	96	96	99	97	98	98	100	100	91	22						100
<i>Klebsiella oxytoca</i>	332		69		94		74	90	94	94	93	99	99	99	96	95	80						91
<i>Klebsiella aerogenes</i> (formerly known as <i>Enterobacter aerogenes</i>)	275		0		88			86	87	99	97	97	99	64	98	99	10						100
<i>Klebsiella sp.</i> ESBL ⁷	87		0		69		0	0	0	66	46	77	76	98	87	43	41						
<i>Pseudomonas aeruginosa</i>	953				89				93	93	90	85	94	94									88
<i>Stenotrophomonas maltophilia</i>	79											84				91							
<i>Enterobacter cloacae</i> complex	336				80			77	80	98	97	98	98	90	97	91	32						100
<i>Proteus mirabilis</i>	785	80	90		100		95	96	97	99	91	93	96	13	100	84							96
<i>Citrobacter freundii</i> complex	199				86			84	85	98	98	97	96	96	100	91	93						100
<i>Citrobacter koseri</i> (diversus)	314				98		98	99	99	100	99	99	99	99	100	99	72						100
<i>Serratia marcescens</i>	129				96			95	98	99	97	95	100	76	98	98							100
<i>Staphylococcus aureus</i>	3474			74		91	(2)				73	74	97			95	100	82	60	100	100	99	
<i>Staphylococcus aureus</i> (MSSA)	2578			100		93	(2)				90	91	98			96	98	83	74	100	100	100	
<i>Staphylococcus aureus</i> (MRSA)	896			0		85	(2)				22	23	95			91	100	80	17	100	100	99	
Coagulase Negative Staph.	37			72		97	(2)				88	88 ⁶	91			89	93	88	72	100	100	100	
<i>Enterococcus spp.</i>	1487	99									90	91 ⁵					97			98	100		
<i>Enterococcus faecalis</i>	1426	100									91	93 ⁵					99			99	99		
<i>Enterococcus faecalis</i> (VRE)	1	100									100	100 ⁵					100			0	100		
<i>Enterococcus faecium</i>	61	69									47	48 ⁵					38			75	98		
<i>Enterococcus faecium</i> (VRE)	14	7									7	7					16			0	100		
<i>Streptococcus pneumoniae</i>	44			100				95				100				41		100	72	100			
≥-5% difference compared to 2020	≥-10% difference compared to 2020		≥+5% difference compared to 2020																				

Footnotes:

1. Profiles include data from disk diffusion, automated testing, and gradient diffusion MIC. Intermediate results have been interpreted as resistant to this tabulation. All isolates were not tested against each antibiotic in the profile.
2. Refer to oxacillin results. Oxacillin susceptible staphylococci can be considered susceptible to:
 - β -lactam combination agents (e.g. piperacillin-tazobactam)
 - Oral cepheims (e.g., cefdinir, cephalexin, cefpodoxime, cefuroxime)
 - Parenteral cepheims including cephalosporins I, II, III, and IV (e.g., cefazolin, Cefepime, cefotaxime, cefotetan, ceftriaxone, cefuroxime, ceftaroline)
 - Carbapenems (e.g. Ertapenem, Imipenem, Meropenem)Oxacillin-resistant strains may not respond to beta-lactam antibiotics such as penicillins, cephalosporins, and carbapenems except Ceftaroline. (CLSI M100, 31th ed, 2021)
3. Data apply only to organisms isolated from the urinary tract.
4. Rifampin should not be used as a sole agent for antimicrobial therapy.
5. Fluoroquinolones are generally not an appropriate therapy against enterococcus infections from sites other than urine.
6. Staphylococcus isolates may develop resistance during prolonged therapy with quinolones. Therefore, isolates that are initially susceptible may become resistant within 3-4 days after initiation of therapy. (CLSI M100, 31th ed, 2021)
7. ESBL rate

	2019	2020	2021
<i>E. coli</i>	6.6%	7.1%	6.8%
<i>Klebsiella sp.</i>	6.1%	6.8%	4.7%

**PACIFIC DIAGNOSTIC LABORATORIES
SANTA BARBARA, CA**

**ANTIBIOTIC SUSCEPTIBILITY PROFILES
2021**

PDL Out Patients only

DEPARTMENT OF MICROBIOLOGY

MONICA R. PHILLIPS, MD
Medical Director
(805) 569-7367

WILLIAM XIE, Ph.D.
Microbiology Specialist
(805) 324-9426

ANDREA HORVATH
Microbiology Lab Manager
(805) 324-9813